Skip to main
MMSI

MMSI Stock Forecast & Price Target

MMSI Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 38%
Buy 50%
Hold 13%
Sell 0%
Strong Sell 0%

Bulls say

Merit Medical Systems is expected to experience mid-single digit organic revenue growth and double-digit earnings growth driven by new products and acquisitions, as well as cost reduction efforts. With management executing on their Continued Growth Initiatives (CGI) program, which focuses on improving operating margins and cash flow, the company's strong balance sheet and growing cash flow should allow for further external growth. However, risks include margin and free cash flow performance as well as slower growth in China.

Bears say

Merit Medical Systems is expected to have sluggish organic revenue growth as compared to the previous quarter, mainly due to a decline in OEM sales. However, with the launch of the WRAPSODY Cell-Impermeable Endoprosthesis and the execution of Continued Growth Initiatives, the company may experience mid-single digit or better organic revenue growth and double-digit EPS growth. If the company achieves 9% or higher organic revenue growth driven by recent acquisitions and new product launches, it could potentially lead to a 24x P/E multiple and a share price of $108.

MMSI has been analyzed by 8 analysts, with a consensus rating of Buy. 38% of analysts recommend a Strong Buy, 50% recommend Buy, 13% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Merit Medical Systems and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Merit Medical Systems (MMSI) Forecast

Analysts have given MMSI a Buy based on their latest research and market trends.

According to 8 analysts, MMSI has a Buy consensus rating as of May 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $92.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $92.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Merit Medical Systems (MMSI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.